Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

This study found that androgenic alopecia at an early age was associated with a lower risk of prostate cancer, contrary to assumptions about androgens' role.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This article proposes that androgenic alopecia might be an evolutionary mechanism for reducing prostate cancer risk by enhancing UV absorption, rather than being a risk factor.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.

This study observed that women with PCOS from Khyber Pakhtunkhwa had significantly higher serum PSA levels, which positively correlated with hirsutism, testosterone, and DHEAS levels compared to healthy controls.

CEC levels may be a useful marker for predicting prostate cancer progression.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Gene variation affects prostate issues and hair loss.

This case-control study found that men with earlier onset androgenetic alopecia, particularly frontal balding, may have an increased risk of prostate cancer in a multiethnic veterans cohort.

This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This review discusses various prostate cancer prevention strategies and reports no new clinical results; the authors highlight the need for ongoing research in this area.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This study observed that in hormone-starved prostate cancer cells, the androgen 5alpha-dihydrotestosterone rapidly induces matriptase activation and shedding, which involves androgen receptor signaling and requires both transcription and protein synthesis.

This review discusses skin diseases in transgender patients receiving gender-affirming hormone therapy and procedures, highlighting unique conditions and the underdiagnosis that affects their quality of life and mental health.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

This study suggests that any baldness, particularly moderate balding, is associated with a higher risk of fatal prostate cancer in men, supporting a possible link between hair loss and prostate cancer mechanisms.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This study found multiple factors, both inherited and acquired, that may lead to bradykinin-mediated angio-oedema, proposing a new classification based on bradykinin production and catabolism imbalance.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.